BiotechTube

Jinfukang oral liquid + Platinum-based doublet chemotherapy

ApprovedUNKNOWN
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Non Small Cell Lung Cancer

Conditions

Non Small Cell Lung Cancer

Trial Timeline

Oct 25, 2021 โ†’ Aug 15, 2024

NCT ID
NCT05098990

About Jinfukang oral liquid + Platinum-based doublet chemotherapy

Jinfukang oral liquid + Platinum-based doublet chemotherapy is a approved stage product being developed by China Resources Pharmaceutical Group for Non Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05098990. Target conditions include Non Small Cell Lung Cancer.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05098990ApprovedUNKNOWN

Competing Products

20 competing products in Non Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
BBP-398 with nivolumabBridgeBio PharmaPhase 1
30
Pemetrexed + CarboplatinEli LillyPhase 3
77
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
SelpercatinibEli LillyPre-clinical
23
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3NanobiotixPhase 1/2
36
PemetrexedEli LillyPre-clinical
23
pemetrexed + erlotinibEli LillyPhase 2
52
LY3295668 ErbumineEli LillyPhase 1
33
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
69
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
pemetrexed + cisplatinEli LillyPhase 2
52
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
pemetrexed + docetaxelEli LillyPhase 3
77
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
52
PemCarbo + Pem onlyEli LillyPhase 3
77
TNG456 + abemaciclibEli LillyPhase 1/2
41
pemetrexed + cisplatinEli LillyPhase 1/2
41

Other Products from China Resources Pharmaceutical Group

Shenfu Zhusheye + 5% glucose injectionApproved
82
Yuxuebi tablet + Placebo tabletApproved
82
Mifepristone tabletsApproved
82
Shenfu Injection + 5% Glucose InjectionApproved
82
Qizhi weitong granules(High๏ผ‰ + Qizhi weitong granules(Low๏ผ‰ + PlaceboPhase 2
49